Meropenem Injection
NDC Package 72485-412-01
Package Information
Meropenem injection is meropenem is used to treat a wide variety of bacterial infections. This formulation utilizes a injection delivery system. Marketed by Armas Pharmaceuticals Inc, this product is identified by NDC 72485-412 and is authorized under FDA application ANDA216154.
Identification & Billing
- RxCUI: 1722934 - meropenem 500 MG Injection
- RxCUI: 1722934 - meropenem (as meropenem trihydrate) 500 MG Injection
- RxCUI: 1722939 - meropenem 1 GM Injection
- RxCUI: 1722939 - meropenem 1000 MG Injection
- RxCUI: 1722939 - meropenem (as meropenem trihydrate) 1000 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72485 - Armas Pharmaceuticals Inc
- 72485-412 - Meropenem
- 72485-412-01 - 1 VIAL in 1 CARTON / 20 mL in 1 VIAL
- 72485-412 - Meropenem
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72485-412). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72485-412-01 identifies a specific commercial package of 1 vial in 1 carton / 20 ml in 1 vial of Meropenem, a human prescription drug labeled by Armas Pharmaceuticals Inc. This injection is formulated for intravenous use and contains meropenem as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Armas Pharmaceuticals Inc on May 31, 2023. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Meropenem is used to treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.
How is this Armas Pharmaceuticals Inc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72485041201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.